5:58 PM
 | 
Feb 04, 2013
 |  BC Extra  |  Clinical News

Emergent's TB vaccine misses in Phase IIb trial

Emergent BioSolutions Inc. (NYSE:EBS) said a single intradermal dose of MVA85A missed the primary efficacy endpoint of reducing the incidence of tuberculosis (TB) infection vs. placebo at a median follow-up of 24.6 months in a Phase IIb trial to prevent TB. Specifically, there were 32 cases (2%) of TB in infants receiving MVA85A vs. 39 cases (3%) in infants receiving placebo...

Read the full 292 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >